Table 4 Baseline medications of study patients
Variable | Group 1 | Group 2 | Group 3 | p value |
|---|---|---|---|---|
(N = 73) | (N = 146) | (N = 29) | ||
ACEI/ARB | 26 (36) | 41 (28) | 16 (55) | 0.017 |
Amiodarone | 14 (19) | 24 (16) | 6 (21) | 0.800 |
Beta blocker | 39 (53) | 69 (47) | 13 (45) | 0.623 |
Digoxin | 7 (10) | 6 (4) | 5 (28) | 0.030 |
Diltiazem | 8 (11) | 14 (10) | 1 (3) | 0.488 |
Dronedarone | 5 (7) | 3 (2) | 1 (3) | 0.202 |
Flecainide | 4 (6) | 12 (8) | 2 (7) | 0.760 |
Pilsicainide | 2 (3) | 1(1) | 0 (0) | 0.346 |
Propafenone | 2 (3) | 18 (12) | 2 (7) | 0.058 |
Sotalol | 0 (0) | 5 (3) | 0 (0) | 0.168 |
Total (class I + III) antiarrhythmics | 27 (37) | 62 (43) | 11 (38) | 0.710 |
NOACs | 40 (55) | 85 (58) | 22 (76) | 0.137 |
Warfarin | 30 (41) | 56 (38) | 7 (24) | 0.265 |
Heparin | 2 (3) | 0 (0) | 0 (0) | 0.089 |
Low molecular weight heparin | 0 (0) | 2 (1) | 0 (0) | 0.494 |
No antithrombotics | 1 (1) | 3 (2) | 0 (0) | 0.711 |